Pfizer to buy

[Anonymous]

Now that Ian is abandoning AZ deal, they are looking at Actavis. This will happen quick so Pfizer can get the tax status they want. Inside of 60 days, we will be Pfizer.

 

[Anonymous]

Now that Ian is abandoning AZ deal, they are looking at Actavis. This will happen quick so Pfizer can get the tax status they want. Inside of 60 days, we will be Pfizer.

"We" won't have jobs, they will be Pfizer "we" hopefully will get the forest severance, and "I" hope it happens. This place is terrible.

 

[Anonymous]

Now that Ian is abandoning AZ deal, they are looking at Actavis. This will happen quick so Pfizer can get the tax status they want. Inside of 60 days, we will be Pfizer.

Yes, I think the future is obvious. We all know that Brent had no intention of being CEO for long. Like he said when he first took over at Forest "I am not looking to sell Forest". You know he is lying when his mouth moves.

He comes in and pimps the car then sells to the highest bidder.

 

[Anonymous]

Please Mr. Pfizer buy us. The morale here is the lowest it has ever been. I want my severance badly.

 

[Anonymous]

"We" won't have jobs, they will be Pfizer "we" hopefully will get the forest severance, and "I" hope it happens. This place is terrible.

This is one of the most sensible posts I've seen on here. Only thing is some will probably make it through to the end.

Do you really want to though? It will just be more of the same. The lucky ones were let go with severance last month. They will have a head start looking and some money in the bank. There is no guarantee Pfizer will honor the change in control severance from Forest. Actavis honored it, but now it's Actavis being bought, not Forest.

 

[Anonymous]

hate to burst your bubble but the pfizer thing is unlikely to happen...too heavily focused on the generics still and the value isn't there for Pfizer. AZ still the favorite..maybe GSK. could be wrong but I am a specialty rep and that makes me smarter than most.

 

[Anonymous]

hate to burst your bubble but the pfizer thing is unlikely to happen...too heavily focused on the generics still and the value isn't there for Pfizer. AZ still the favorite..maybe GSK. could be wrong but I am a specialty rep and that makes me smarter than most.

If you are FSR1, I'll take your word for it. All other specialty are in PCP category as far as I'm concerned, only care to hear what the elite specialists have to say.

 

[Anonymous]

hate to burst your bubble but the pfizer thing is unlikely to happen...too heavily focused on the generics still and the value isn't there for Pfizer. AZ still the favorite..maybe GSK. could be wrong but I am a specialty rep and that makes me smarter than most.

Yeah you're wrong. Pfizer spokesperson announced yesterday they are no longer considering AZ. Don't you people read the news? Actavis is now rated as a "buy'.

 

[Anonymous]

hate to burst your bubble but the pfizer thing is unlikely to happen...too heavily focused on the generics still and the value isn't there for Pfizer. AZ still the favorite..maybe GSK. could be wrong but I am a specialty rep and that makes me smarter than most.

Those were the reports about three weeks ago. You haven't been paying too much attention the last 48 hrs have you?

Remember, they can buy product lines and sell product lines any time they want. They need the inversion. That value is the same no matter who they buy.

AZ doesn't want to sell. I am not BS, PB and good old CI, but I bet they are waving the "for sale" flag.

 

[Silly_Forest_Rep]

hate to burst your bubble but the pfizer thing is unlikely to happen...too heavily focused on the generics still and the value isn't there for Pfizer. AZ still the favorite..maybe GSK. could be wrong but I am a specialty rep and that makes me smarter than most.

Topics: M&A
Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets
September 11, 2014 | By Tracy Staton
SHARE





TOOLS
Comment
Print
Contact Author
Reprint
Pfizer needs a tax inversion deal. Without one, it can't properly compete with overseas companies, simple as that. And if AstraZeneca doesn't want to play, Pfizer is willing to look elsewhere. Even if "elsewhere" means a generics company.

That's what executives told the high-profile Bernstein Research analyst Tim Anderson, according to a note to investors Thursday morning--basically confirming the deal talk that's been rumbling since Pfizer ($PFE) backed away from its AstraZeneca ($AZN) bid in late May.

With its cost-cutting program coming to a close, the company wants to slash its tax rate to get another efficiency boost--and to give it a better hand in playing for overseas M&A. European companies have had "a substantial advantage" making deals because of their lower tax burden, Pfizer figures (as noted by Anderson). Plus, it needs access to that cash it's storing overseas for tax-avoidance reasons.



An inversion deal can deliver all that. And the company's top brass apparently see several possibilities. An asset swap, for instance. It would have to be a big asset swap to meet the legal requirements for moving its "home" overseas, and portfolios and business units large enough are few and far between--but there are some opportunities, they told Anderson.

Then there's AstraZeneca, of course. Pfizer can't say much about that prospect because of U.K. takeover rules. Anderson figures it's "reasonably likely" that Pfizer will come back to try to parlay, but the analyst also says that Pfizer seems to suggest that AstraZeneca doesn't offer "a highly unique, must-have portfolio."

Hence the looking elsewhere. And, somewhat surprisingly, the company would consider a big generics player. That sort of deal, provided it's large enough to achieve an inversion, would not only satisfy Pfizer's craving for lower taxes, but also help beef up its established products business. And that's something Pfizer would like to do. In fact, if Pfizer really wants to spin off its Global Established Products unit in a few years, then it's going to have to bulk up in off-patent meds.

Plus, if Pfizer could fold a big portfolio of established products into its own infrastructure, it could cut costs. Biosimilars and hard-to-produce generics would be ideal, the execs suggested.

There's a "substantial possibility" that the generic unit would be better off as a standalone company," the execs told Anderson. But it needs a boost to make it a "full-fledged standalone business," the note states.

Buying AstraZeneca would do the trick, but so would buying a company like Actavis ($ACT), which is one of the targets that's been bandied about in recent weeks. In early August, Berenberg analysts touted GlaxoSmithKline ($GSK) as a merger partner.

Late last month, ISI Group analyst Mark Schoenebaum sent out a note revealing the results of a client survey--obviously not scientific--about which inversion buy Pfizer should make, given those three choices. AstraZeneca got about 47% of the vote, with Actavis at about 38%. Glaxo? Way down below 10%--about equal to those who said Pfizer shouldn't buy any of them.

 

[Anonymous]

hate to burst your bubble but the pfizer thing is unlikely to happen...too heavily focused on the generics still and the value isn't there for Pfizer. AZ still the favorite..maybe GSK. could be wrong but I am a specialty rep and that makes me smarter than most.

Pfizer's intent is tax inversion. They can buy ACT at a discount to AZ, spin off the generic division to another company to recoupe so dough, and they still get their tax savings. Or they can simply combine the genetics with their own generics division and gain market share, shut down the ACT plants and increase profit margin. ACT earnings are accretive (and made up of 50% branded products). How is AZ a better deal?

 

[Anonymous]

Pfizer's intent is tax inversion. They can buy ACT at a discount to AZ, spin off the generic division to another company to recoupe so dough, and they still get their tax savings. Or they can simply combine the genetics with their own generics division and gain market share, shut down the ACT plants and increase profit margin. ACT earnings are accretive (and made up of 50% branded products). How is AZ a better deal?

At a discount? Would the overall price be less? Sure bc our market cap is less than AZ, but not even close if you look at our stock price. We are at 240$ per share, triple the AZ price. Not saying they can't do it of course but they won't take that stock price lightly.

 

[Anonymous]

It is not the stock price that makes a difference as much as the market capitalization. It is not as if there are equal number of shares per company times the stick price.
Hello? That would make Actavis higher in market cap which it isn't!

You don't get that, do you??

 

[Anonymous]

It is not the stock price that makes a difference as much as the market capitalization. It is not as if there are equal number of shares per company times the stock price.
Hello? That would make Actavis higher in market cap which it isn't!

You don't get that, do you??

 

[Anonymous]

At a discount? Would the overall price be less? Sure bc our market cap is less than AZ, but not even close if you look at our stock price. We are at 240$ per share, triple the AZ price. Not saying they can't do it of course but they won't take that stock price lightly.

Please..let th FSR1 reps discuss the buyout and you territory reps can just focus on getting your sigs everyday. Stock price has nothing to do with the purchase price, moron. No..wait, Pfizer shares are only $30 right now. That must mean Actavis is 8-9 times more valuable than Pfizer, why the hell aren't we the ones trying to by them???

 

[Anonymous]

wow. you guys are IDIOTS. this is hysterical.

Pfizer WILL be buying us. Do your homework, maybe study up on M & A's, and learn the rules of tax inversion.

 

[Anonymous]

Pfizer has no other choice. It's already an imminent fact in Home Office. We are gone, not if but when.

 

[Anonymous]

At a discount? Would the overall price be less? Sure bc our market cap is less than AZ, but not even close if you look at our stock price. We are at 240$ per share, triple the AZ price. Not saying they can't do it of course but they won't take that stock price

Go back to school. Market cap = outstanding shares X share price. Yes stock price is higher but shares outstanding is only 260,000,000.

 

[Anonymous]

yep i'm in home office. we are already talking about when Pfizer takes over

 

[Anonymous]

At a discount? Would the overall price be less? Sure bc our market cap is less than AZ, but not even close if you look at our stock price. We are at 240$ per share, triple the AZ price. Not saying they can't do it of course but they won't take that stock price

Go back to school. Market cap = outstanding shares X share price. Yes stock price is higher but shares outstanding is only 260,000,000.

That wasn't my point, maybe I did not state it correctly. I realize AZ and Pfizer are much bigger regardless of share price, and Pfizer has the ability to make it happen no matter what. I was simply stating that as the stock goes up the Actavis board will certainly demand a hefty premium. If Pfizer wants us at any cost, it's going to happen. But it's not a hostile takeover, so it still comes down to how much they are willing to offer and the board approving.